- Home
- SRPT vs REXR Comparison
SRPT vs REXR Comparison
Compare SRPT & REXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- REXR
- Stock Information
- Founded
- SRPT 1980
- REXR 2013
- Country
- SRPT United States
- REXR United States
- Employees
- SRPT N/A
- REXR N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- REXR Real Estate Investment Trusts
- Sector
- SRPT Health Care
- REXR Real Estate
- Exchange
- SRPT Nasdaq
- REXR Nasdaq
- Market Cap
- SRPT 9.8B
- REXR N/A
- IPO Year
- SRPT 1997
- REXR 2013
- Fundamental
- Price
- SRPT $70.40
- REXR $39.39
- Analyst Decision
- SRPT Buy
- REXR Hold
- Analyst Count
- SRPT 21
- REXR 10
- Target Price
- SRPT $164.05
- REXR $47.50
- AVG Volume (30 Days)
- SRPT 2.2M
- REXR 2.6M
- Earning Date
- SRPT 04-30-2025
- REXR 04-16-2025
- Dividend Yield
- SRPT N/A
- REXR 4.31%
- EPS Growth
- SRPT N/A
- REXR 7.14
- EPS
- SRPT 2.34
- REXR 1.20
- Revenue
- SRPT $1,901,979,000.00
- REXR $936,407,000.00
- Revenue This Year
- SRPT $67.83
- REXR $11.38
- Revenue Next Year
- SRPT $25.66
- REXR $11.60
- P/E Ratio
- SRPT $30.71
- REXR $33.27
- Revenue Growth
- SRPT 52.97
- REXR 17.37
- 52 Week Low
- SRPT $70.91
- REXR $36.92
- 52 Week High
- SRPT $173.25
- REXR $52.61
- Technical
- Relative Strength Index (RSI)
- SRPT 28.10
- REXR 47.42
- Support Level
- SRPT $70.91
- REXR $38.79
- Resistance Level
- SRPT $76.67
- REXR $40.56
- Average True Range (ATR)
- SRPT 4.03
- REXR 0.99
- MACD
- SRPT -1.50
- REXR -0.03
- Stochastic Oscillator
- SRPT 2.28
- REXR 42.86
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.